Clint Brannon Discusses PTAB's Decision on IPR Depositions with Law360

In July, a decision from the Patent Trial and Appeal Board (PTAB) in Focal Therapeutics v. SenoRx clarified its rules for depositions in inter partes review. Williams Mullen intellectual property attorney Clint Brannon discussed the decision and its impact for a recent article on Law360. 

"Why this is important in the context of PTAB proceedings is that different panels were maybe taking different views of what the rule is,” said Clint Brannon of Williams Mullen. “For these kinds of matters you need consistency so that, independent of which panel I have, I know when I can talk to my witness and when I can’t.”

The full article is available to Law360 subscribers here.